The U.S. Food and Drug Administration on Thursday approved a new protocol for a post-marketing study of Bayer AG’s Essure birth-control device, as the regulator seeks more information on the device’s safety.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,